Zydus Cadila receive USFDA’s tentative approval for Aripiprazole Orally Disintegrating Tablets

31 Jul 2012 Evaluate

Zydus Cadila, an innovative global pharmaceutical company, has received tentative approval from USFDA for Aripiprazole Orally Disintegrating Tablets in the strengths of 10 mg, 15 mg, 20 mg and 30 mg. The drug is an anti-phychotic medication used in the treatment of schizophrenia.

Recently, the company entered into a settlement and license agreement with Somaxon Pharmaceuticals, and ProCom One to resolve pending patent litigation involving Silenor (Doxepin) 3 mg and 6 mg tablets.

Flagship company of Zydus Cadila Group, it focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.

Zydus Lifesciences Share Price

884.85 8.75 (1.00%)
22-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1634.40
Dr. Reddys Lab 1217.15
Cipla 1371.55
Zydus Lifesciences 884.85
Lupin 2165.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×